Tokyo, Dec 17, 2014 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it has been listed for the 13th consecutive year since 2002 in the FTSE4Good Index Series, a global index for socially responsible investment.
The FTSE4Good Index Series is a selection of companies that meet designated standards in three aspects of environment, society and governance, as chosen by the FTSE Group, a 100% wholly owned subsidiary of the London Stock Exchange. As at the end of November 2014, a total of 781 companies from around the world have been selected for the FTSE4Good Index Series, including 176 companies from Japan.
Along with being listed in the FTSE4Good Index Series, Eisai is also listed in the Dow Jones Sustainability Asia Pacific Index, another representative index for socially responsible investment.
Eisai's corporate philosophy is to give first thought to patients and their families and increase the benefits that health care provides as well as address diverse healthcare needs worldwide. Guided by this philosophy, Eisai will continue to develop innovative new drugs and make them available to patients around the world as early as possible to fulfill its social responsibility and secure the trust of stakeholders.
About Eisai
Eisai Co., Ltd. (TSE: 4523; ADR: ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.
Source: Eisai
Contact:
Copyright 2014 JCN Newswire. All rights reserved. www.japancorp.net
The FTSE4Good Index Series is a selection of companies that meet designated standards in three aspects of environment, society and governance, as chosen by the FTSE Group, a 100% wholly owned subsidiary of the London Stock Exchange. As at the end of November 2014, a total of 781 companies from around the world have been selected for the FTSE4Good Index Series, including 176 companies from Japan.
Along with being listed in the FTSE4Good Index Series, Eisai is also listed in the Dow Jones Sustainability Asia Pacific Index, another representative index for socially responsible investment.
Eisai's corporate philosophy is to give first thought to patients and their families and increase the benefits that health care provides as well as address diverse healthcare needs worldwide. Guided by this philosophy, Eisai will continue to develop innovative new drugs and make them available to patients around the world as early as possible to fulfill its social responsibility and secure the trust of stakeholders.
About Eisai
Eisai Co., Ltd. (TSE: 4523; ADR: ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.
Source: Eisai
Contact:
Public Relations Department, Eisai Co., Ltd. +81-3-3817-5120
Copyright 2014 JCN Newswire. All rights reserved. www.japancorp.net